Amereican Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S135-S151.
2.
AlicicRZRooneyMTTuttleKR.Diabetic kidney disease. Clin J Am Soc Nephrol. 2017;12(12):2032-2045.
3.
GórrizJLNavarro-GonzálezJFOrtizA, et al. Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease. Nephrol Dial Transplant. 2020;35(suppl 1):i13-i23.
4.
NealBPerkovicVMahaffeyKW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657.
5.
WiviottSDRazIBonacaMP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347-357.
6.
ZinmanBWannerCLachinJM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
7.
WannerCInzucchiSEZinmanB.Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(18):1801-1802.
ZelnikerTAWiviottSDRazI, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139(17):2022-2031.
12.
ZelnikerTAWiviottSDRazI, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet (London, England). 2019;393(10166):31-39.
